AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further ...
Source: businessinsider.com
Stay updated with breaking news from Action Implementation Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further ...
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA...